Reuters logo
BRIEF-TapImmune says 280-patient efficacy trial sponsored by Mayo Clinic evaluating TPIV200 efficacy expected to begin by year end 2017​
November 14, 2017 / 12:12 PM / 6 days ago

BRIEF-TapImmune says 280-patient efficacy trial sponsored by Mayo Clinic evaluating TPIV200 efficacy expected to begin by year end 2017​

Nov 14 (Reuters) - TapImmune Inc:

* TapImmune Inc - 280-patient efficacy trial sponsored by Mayo Clinic evaluating TPIV200 efficacy expected to begin by year end 2017​

* TapImmune - ‍enrolled final patient in randomized Phase 2 clinical study of novel T-cell vaccine candidate TPIV200

* TapImmune Inc - ‍look forward to reporting interim immunogenicity results in first half of 2018 from TPIV200 study​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below